Abstract: An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.
Type:
Grant
Filed:
April 11, 2001
Date of Patent:
November 8, 2005
Assignee:
Biogen, Inc.
Inventors:
Blake Pepinsky, Laura Runkel, Margot Brickelmaier, Adrian Whitty, Paula Hochman
Abstract: The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.
Type:
Grant
Filed:
November 28, 2000
Date of Patent:
April 5, 2005
Assignee:
Biogen, Inc.
Inventors:
Ko-Chung Lin, Steven P. Adams, Alfredo C. Castro, Craig N. Zimmerman, Julio Hernan Cuervo, Wen-Cherng Lee, Charles E. Hammond, Mary Beth Carter, Ronald G. Almquist
Abstract: Nucleotide and amino acid sequences are provided for compounds which promote tissue growth, as well as methods for modulating tissue growth, for imaging tissues and organs, and for treating patients.
Type:
Grant
Filed:
January 21, 2000
Date of Patent:
March 1, 2005
Assignee:
Biogen, Inc.
Inventors:
Michele Sanicola-Nadel, Catherine Hession, Richard L. Cate, Dane S. Worley
Abstract: DNA sequences, recombinant DNA molecules and hosts transformed with them which produce polypeptides displaying a biological or immunological activity of human interferon, the genes coding for these polypeptides and methods of making and using these molecules, hosts, genes and polypeptides. The DNA sequences are characterized in that they code for a polypeptide displaying a biological or immunological activity of human interferon. In appropriate hosts these DNA sequences and recombinant DNA molecules permit the production and identification of genes and polypeptides displaying a biological or immunological activity of human interferon and their use in antiviral and antitumor or anticancer agents.
Abstract: A fusion polypeptide is described having the amino acid sequence X-Y-Z, or portion thereof, comprising the amino acid sequence of a glycosylated interferon-beta (X); Y is an optional linker moiety; and Z is a polypeptide comprising at least a portion of a polypeptide other than glycosylated interferon-beta. It is preferred that X is human interferon-beta-1a. Mutants of interferon-beta-1a are also described.
Type:
Grant
Filed:
April 11, 2001
Date of Patent:
October 5, 2004
Assignee:
Biogen, Inc.
Inventors:
Adrian Whitty, Laura Runkel, Margot Brickelmaier, Paula Hochman
Abstract: Methods of using inhibitors of the CD2/LFA-3 interaction in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in mammals, including humans. Such conditions include psoriasis, UV damage, e.g., photoaging, atopic dermatitis, cutaneous T cell lymphoma such as mycosis fungoides, allergic and irritant contact dermatitis, lichen planus, alopecia areata, pyoderma gangrenosum, vitiligo, ocular cicatricial pemphigoid, and urticaria.
Type:
Grant
Filed:
December 5, 2000
Date of Patent:
July 20, 2004
Assignees:
Biogen, Inc., The Regents of University of Michigan
Abstract: Methods of using inhibitors of the CD2/LFA-3 interaction in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in mammals, including humans. Such conditions include psoriasis, UV damage, e.g., photoaging, atopic dermatitis, cutaneous T cell lymphoma such as mycosis fungoides, allergic and irritant contact dermatitis, lichen planus, alopecia areata, pyoderma gangrenosum, vitiligo, ocular cicatricial pemphigoid, and urticaria.
Type:
Application
Filed:
February 13, 2004
Publication date:
July 15, 2004
Applicants:
Biogen, Inc., a Massachusetts Corporation, The Regents of the University of Michigan, Ann Arbor, Michigan Corporation
Abstract: The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable.
Type:
Application
Filed:
August 21, 2003
Publication date:
April 8, 2004
Applicant:
Biogen, Inc.
Inventors:
William F. Kiesman, Carol L. Ensinger, Russell C. Petter, James E. Dowling, Gnanasambandam Kumaravel, He Xi Chang, Ko Chung Lin
Abstract: The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.
Type:
Application
Filed:
October 1, 2002
Publication date:
March 18, 2004
Applicant:
Biogen, Inc. a Massachusetts Corporation.
Inventors:
Zhongli Zheng, Carol L. Ensinger, Steven P. Adams
Abstract: Methods and pharmaceutical compositions for modifying cells of a mammalian recipient with DNA encoding a secreted protein such as human interferon in situ are provided. The methods include forming a secreted protein expression system in vivo or ex vivo and administering the expression system to the mammalian recipient. The expression system and methods are useful for the localized and systemic delivery of interferons in situ.
Abstract: The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.
Type:
Grant
Filed:
January 25, 1999
Date of Patent:
February 3, 2004
Assignee:
Biogen, Inc.
Inventors:
Zhongli Zheng, Carol L. Ensinger, Steven P. Adams
Abstract: Nucleotide and amino acid sequences are provided for compounds which promote tissue growth, as well as methods for modulating tissue growth, for imaging tissues and organs, and for treating patients. Isolated nucleic acid and amino acid sequences for Ret ligands are disclosed. Ret ligands encoded by the isolated nucleic acid sequences of the invention have a hydrophobic N-terminal signal sequence, a hydrophobic C-terminal sequence and a phosphatidylinositol glycan linkage motif. Vectors and host cells that include Ret ligands encoded by the isolated nucleic acid sequences of the invention are also disclosed.
Type:
Grant
Filed:
November 6, 1998
Date of Patent:
January 13, 2004
Assignee:
Biogen, Inc.
Inventors:
Michele Sanicola-Nadel, Catherine Hession, Richard L. Cate, Dane S. Worley
Abstract: This invention relates to compositions and methods comprising “lymphotoxin-&bgr; receptor blocking agents”, which block lymphotoxin-&bgr; receptor signalling. Lymphotoxin-&bgr; receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-&bgr; receptor extracellular domain that act as lymphotoxin-&bgr; receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-&bgr; receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-&bgr; receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-&bgr; receptor signalling is provided.
Type:
Grant
Filed:
April 30, 1999
Date of Patent:
December 30, 2003
Assignee:
Biogen, Inc.
Inventors:
Jeffrey L. Browning, Christopher D. Benjamin, Paula S. Hochman
Abstract: The present invention is based on the discovery that CRIPTO mutants each comprising at least one amino acid substitution from a CRIPTO polypeptide demonstrate tumor blocking activity.
Type:
Application
Filed:
March 17, 2003
Publication date:
December 18, 2003
Applicant:
BIOGEN, INC.
Inventors:
Kevin P. Williams, Susan Foley, Susan Schiffer, Bruno Domon, Michele Sanicola-Nadel
Abstract: Proteins which are upregulated in injured or regenerating tissues, as well as the DNA encoding these proteins, are disclosed, as well as therapeutic compositions and methods of treatment encompassing these compounds.
Type:
Grant
Filed:
November 23, 1998
Date of Patent:
December 16, 2003
Assignee:
Biogen, Inc.
Inventors:
Michele Sanicola-Nadel, Joseph V. Bonventre, Catherine Hession, Takaharu Ichimura, Henry Wei, Richard L. Cate
Abstract: Methods and pharmaceutical compositions for modifying cells of a mammalian recipient with DNA encoding a secreted protein such as human interferon in situ are provided. The methods include forming a secreted protein expression system in vivo or ex vivo and administering the expression system to the mammalian recipient. The expression system and methods are useful for the localized and systemic delivery of interferons in situ.
Abstract: The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable.
Type:
Application
Filed:
June 12, 2003
Publication date:
December 4, 2003
Applicant:
Biogen, Inc.
Inventors:
Carol L. Ensinger, James E. Dowling, Russell C. Petter, Gnanasambandam Kumaravel
Abstract: Disclosed is a method of treating fibrosis in a human or animal subject. The method comprises administering to the subject an effective amount of an antibody to an integrin or fragment thereof.
Abstract: The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be usefull in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable.
In one embodiment, the invention features a compound of formula I:
wherein:
R3 is an optionally substituted bicyclic, tricylic, or pentacyclic group selected from:
and wherein R1, R2, R6, X1, X2, and Z are as described in the specification.
Type:
Grant
Filed:
November 13, 2000
Date of Patent:
November 18, 2003
Assignee:
Biogen, Inc.
Inventors:
William F. Kiesman, Carol L. Ensinger, Russell C. Petter, James E. Dowling, Gnanasambandam Kumaravel, He Xi Chang, Ko Chung Lin